Literature DB >> 16611072

Destroying RNA as a therapeutic approach.

Alaeddin Tafech1, Tyler Bassett, Dan Sparanese, Chow H Lee.   

Abstract

The ability to target RNA, mRNA and viral RNA in particular, for degradation is a powerful approach in molecular biology and pharmacology. Such approaches can be used in the study of gene function as in functional genomics, in the identification of disease-associated genes, and for the treatment of human diseases. This review provides a comprehensive up-to-date look at all the current available technologies used for the destruction of RNA, with a focus on their therapeutic potential. This includes approaches that utilize the activity of protein ribonucleases such as antisense oligonucleotide, small interfering RNA, RNase P-associated external guide sequence, onconase and bovine seminal RNase. Sequence-specific approaches that do not utilize activity of protein ribonucleases, such as ribozyme and DNazyme, are also reviewed and discussed. This review should provide a useful starting framework for researchers interested in using the RNA-destruction methodologies on the bench and in the clinic, and serves as a stimulus for further development of novel and more potent RNA degradation technologies. This is particularly critical, given the anticipation of discoveries of new cellular RNA degradation machineries and human diseases that are associated with dysfunctional RNA molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611072     DOI: 10.2174/092986706776361021

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

Review 2.  Role of the Ribonuclease ONCONASE in miRNA Biogenesis and tRNA Processing: Focus on Cancer and Viral Infections.

Authors:  Marta Menegazzi; Giovanni Gotte
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

Review 3.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

4.  Structural basis for catalysis by onconase.

Authors:  J Eugene Lee; Euiyoung Bae; Craig A Bingman; George N Phillips; Ronald T Raines
Journal:  J Mol Biol       Date:  2007-10-04       Impact factor: 5.469

Review 5.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

Review 6.  Factors interacting with HIF-1alpha mRNA: novel therapeutic targets.

Authors:  Stefanie Galbán; Myriam Gorospe
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

7.  Sulforaphane potentiates RNA damage induced by different xenobiotics.

Authors:  Carmela Fimognari; Monia Lenzi; Piero Sestili; Eleonora Turrini; Lorenzo Ferruzzi; Patrizia Hrelia; Giorgio Cantelli-Forti
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

8.  New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.

Authors:  O A Patutina; N L Mironova; V V Vlassov; M A Zenkova
Journal:  Acta Naturae       Date:  2009-07       Impact factor: 1.845

9.  Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies.

Authors:  Woo-Ram Lee; Ji-Young Jang; Jeong-Sun Kim; Myung-Hee Kwon; Yong-Sung Kim
Journal:  Nucleic Acids Res       Date:  2009-12-09       Impact factor: 16.971

10.  Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos.

Authors:  Anne Dallas; Svetlana V Balatskaya; Tai-Chih Kuo; Heini Ilves; Alexander V Vlassov; Roger L Kaspar; Kevin O Kisich; Sergei A Kazakov; Brian H Johnston
Journal:  Nucleic Acids Res       Date:  2008-10-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.